Published in Genes Chromosomes Cancer on September 01, 2002
DNA hypomethylation in cancer cells. Epigenomics (2009) 3.71
Human transposon tectonics. Cell (2012) 1.81
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer (2004) 1.41
L1 retrotransposons in human cancers. J Biomed Biotechnol (2006) 1.34
Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res (2008) 1.27
Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenetics (2011) 1.26
In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One (2008) 1.24
The context and potential of epigenetics in oncology. Br J Cancer (2009) 1.20
Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res (2008) 1.19
Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev (2004) 1.15
Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med (2006) 1.12
Replication independent DNA double-strand break retention may prevent genomic instability. Mol Cancer (2010) 1.09
LINE-1 hypomethylation in a choline-deficiency-induced liver cancer in rats: dependence on feeding period. J Biomed Biotechnol (2006) 1.00
Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (2011) 1.00
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer (2007) 0.98
Vezf1 regulates genomic DNA methylation through its effects on expression of DNA methyltransferase Dnmt3b. Genes Dev (2008) 0.98
Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch (2008) 0.94
Deregulation of an imprinted gene network in prostate cancer. Epigenetics (2014) 0.93
Mobilizing diversity: transposable element insertions in genetic variation and disease. Mob DNA (2010) 0.93
Epigenetic contributions to cancer metastasis. Clin Exp Metastasis (2008) 0.93
Epigenetics in prostate cancer. Prostate Cancer (2011) 0.92
Human RecQL4 helicase plays critical roles in prostate carcinogenesis. Cancer Res (2010) 0.91
A dose-response study of arsenic exposure and global methylation of peripheral blood mononuclear cell DNA in Bangladeshi adults. Environ Health Perspect (2013) 0.89
Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics (2010) 0.89
Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One (2014) 0.83
Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone. J Biol Chem (2016) 0.82
Prostate cancer epigenetics: a review on gene regulation. Gene Regul Syst Bio (2007) 0.81
LINE-1 and Alu hypomethylation in mucoepidermoid carcinoma. BMC Clin Pathol (2013) 0.80
Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. Nucleic Acids Res (2015) 0.80
Epigenetic regulation of prostate cancer. Clin Epigenetics (2011) 0.79
Towards understanding the epigenetics of transcription by chromatin structure and the nuclear matrix. Gene Ther Mol Biol (2005) 0.79
Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation. Oncotarget (2016) 0.78
PROTEOME-3D: an interactive bioinformatics tool for large-scale data exploration and knowledge discovery. Mol Cell Proteomics (2003) 0.78
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget (2016) 0.77
Role of diet in prostate cancer: the epigenetic link. Oncogene (2014) 0.76
LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality. Epigenetics (2016) 0.75
Performance of Different Analytical Software Packages in Quantification of DNA Methylation by Pyrosequencing. PLoS One (2016) 0.75
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res (2010) 2.95
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases. Eur Urol (2008) 2.42
Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res (2002) 2.34
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol (2005) 2.03
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.65
CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene (2005) 1.63
Laser fibre deterioration and loss of power output during photo-selective 80-w potassium-titanyl-phosphate laser vaporisation of the prostate. Eur Urol (2008) 1.62
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res (2002) 1.54
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res (2009) 1.54
Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol (2012) 1.53
Downregulation of several fibulin genes in prostate cancer. Prostate (2007) 1.46
miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer (2010) 1.42
Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.40
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res (2010) 1.33
The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J Biol Chem (2005) 1.33
Probabilistic analysis of gene expression measurements from heterogeneous tissues. Bioinformatics (2010) 1.31
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31
Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol (2007) 1.30
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer (2006) 1.30
Androgen regulation of micro-RNAs in prostate cancer. Prostate (2010) 1.30
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol (2013) 1.30
Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet (2010) 1.29
Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol (2002) 1.29
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res (2003) 1.21
CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia (2009) 1.21
Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer (2010) 1.21
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology (2007) 1.19
Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res (2004) 1.17
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res (2004) 1.15
Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate (2014) 1.14
Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol (2006) 1.13
RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer (2004) 1.13
Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate (2010) 1.12
Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res (2005) 1.12
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer (2005) 1.11
Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma. Int J Cancer (2003) 1.10
Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol (2008) 1.09
Molecular mechanisms of prostate cancer. Eur Urol (2004) 1.08
Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer (2005) 1.08
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res (2014) 1.08
Chromosomal aberrations in prostate cancer. Front Biosci (2007) 1.07
Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther (2007) 1.05
ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One (2011) 1.05
HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2013) 1.03
Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol (2010) 1.03
Desmoplastic fibroma of the mandible--review of the literature and presentation of a rare case. Head Face Med (2009) 1.01
Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol (2008) 0.99
Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate. Lab Invest (2002) 0.99
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer (2002) 0.99
DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther (2006) 0.99
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer (2007) 0.98
Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer (2005) 0.98
Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol (2009) 0.97
Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics (2010) 0.96
Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab Invest (2002) 0.94
Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem (2005) 0.93
Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int (2011) 0.93
Delayed infection of a pelvic lymphocele following robotic radical prostatectomy and pelvic lymphadenectomy: two cases. Urol Int (2009) 0.93
Characteristics of testicular dysgenesis syndrome and decreased expression of SRY and SOX9 in Frasier syndrome. Mol Reprod Dev (2008) 0.93
The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer (2011) 0.93
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest (2012) 0.92
Androgen regulation of the androgen receptor coregulators. BMC Cancer (2008) 0.92
Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother Pharmacol (2004) 0.92
Expression of ERalpha and ERbeta in prostate cancer. Prostate (2003) 0.92
Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Genes Chromosomes Cancer (2005) 0.91
Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. Mutat Res (2007) 0.91
Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol (2006) 0.91
Overexpression of EIF3S3 promotes cancer cell growth. Prostate (2006) 0.91
Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer. Int J Cancer (2008) 0.91
Lithium triborate laser vaporization of the prostate using the 120 W, high performance system laser: high performance all the way? J Urol (2011) 0.91
Human pHyde is not a classical tumor suppressor gene in prostate cancer. Int J Cancer (2003) 0.90
Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol Cancer Res (2006) 0.89
Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J Cell Physiol (2005) 0.89
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. BJU Int (2006) 0.89
Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol (2012) 0.89